178 related articles for article (PubMed ID: 29228226)
1. Vedolizumab-Associated Pancreatitis in Paediatric Ulcerative Colitis: Functional Selectivity of the α4β7integrin and MAdCAM-1 Pathway?
Lopez RN; Gupta N; Lemberg DA
J Crohns Colitis; 2018 Mar; 12(4):507-508. PubMed ID: 29228226
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
3. Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.
Lin E; Katz S
Inflamm Bowel Dis; 2020 Apr; 26(5):e44. PubMed ID: 32100867
[No Abstract] [Full Text] [Related]
4. Vedolizumab-induced acute pancreatitis: the first reported clinical case.
Picardo S; So K; Venugopal K; Chin M
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305366
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
6. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
[TBL] [Abstract][Full Text] [Related]
7. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
8. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
[TBL] [Abstract][Full Text] [Related]
10. [Vedolizumab in the treatment of Crohn's disease].
Gisbert JP; Domènech E
Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
12. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Ravn CD; Bendix M; Lyhne S
Ugeskr Laeger; 2024 May; 186(22):. PubMed ID: 38847300
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
15. Acneiform eruption induced by vedolizumab.
Magdaleno-Tapial J; Ferrer-Guillén B; Valenzuela-Oñate C; Esteve-Martínez A
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677821
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
17. Psoriasis Induced by Vedolizumab.
Sody E; Körber A
Inflamm Bowel Dis; 2017 Feb; 23(2):E9-E11. PubMed ID: 28107281
[No Abstract] [Full Text] [Related]
18. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Wyant T; Estevam J; Yang L; Rosario M
Cytometry B Clin Cytom; 2016 Mar; 90(2):168-76. PubMed ID: 25908521
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab-Associated Acute Respiratory Distress Syndrome.
Nambiar S; Karippot A; Oliver T
Am J Ther; 2018; 25(5):e592-e593. PubMed ID: 29189313
[No Abstract] [Full Text] [Related]
[Next] [New Search]